-
2023-503378-19-00
5
2018-08-23
Chronic Plaque Psoriasis
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2023-504581-29-00
7
2018-04-26
Multiple myeloma
-
2023-508726-10-00
5
2018-03-28
Hepatocellular Carcinoma
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-510840-30-00
4
2017-12-01
Hormone Naive Prostate Cancer
-
2023-506399-28-00
5
2017-11-08
Crohn's Disease
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-507500-31-00
10
2017-08-22
Advanced or metastatic Non-small cell lung cancer (NSCLC)
-
2023-504951-29-00
5
2017-07-27
Chron's Disease
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2022-501017-31-00
5
2016-05-10
Rheumatoid arthritis
-
2023-505246-26-00
5
2016-01-27
High- or very-high risk, localized or locally advanced prostate cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2023-510453-41-00
5
2015-10-26
Castration resistant prostate cancer patients metastatic to bone.
-
2023-509136-25-00
5
2015-07-16
Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2023-503423-25-00
5
2014-06-19
Burkitt lymphoma
-
2024-517622-25-00
5
2013-12-06
Patients with localized prostate cancer and high-risk features of rela
-
2023-507091-47-00
1
2025-02-10
Advanced or metastatic solid tumors
-
2023-505096-68-00
4
2025-01-14
Preclinical Alzheimer’s Disease
-
2022-502049-91-00
4
2023-09-26
SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
-
2023-508998-85-00
1
2025-01-28
Metastatic pancreatic ductal adenocarcinoma (mPDAC)